ArticleBMC infectious diseases2026
Infectious consequences of antimicrobial change from vancomycin-piperacillin/ tazobactam to vancomycin-cefepime in the prevention of AKI during orthotopic heart transplantation.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpiric antimicrobial selection in orthotopic heart transplantation (OHT) is critically important as post-operative infections are a significant cause of morbidity and mortality. While variability of antimicrobial selection exists between centers, both combinations of vancomycin and piperacillin-tazobactam (VPT) and vancomycin and cefepime (VC) are frequently used. VPT drug combination has been associated with increased risk of acute kidney injury (AKI) in multiple reports. Our study aimed to evaluate the infectious impact of changing the empiric antimicrobial selection from VPT to VC.
methodsThis was a single-center study in patients who underwent OHT at the Medical University of South Carolina (MUSC) from 2015 through 2021 (n=120). As part of a quality improvement measure, the empiric intraoperative antimicrobial therapy was transitioned from VPT (n=48) to VC (n=72) on 6/20/2019, providing a prospective setting to investigate infectious outcomes.
resultsA total of 10.4% of patients who received VPT had a positive culture within 30 days of OHT, compared to 9.7% of patients who received VC (p=0.781). All positive cultures were reviewed and deemed to be clinically significant infections. No significant difference in the site of culture positivity was identified between groups (p=0.487). Among patients who developed postoperative infection, there was a trend toward a longer time to infection in patients receiving VPT (median 28 days) than VC (median 14 days), p=0.08.
conclusionsCulture-positive infections within 30 days post-OHT were similar between patients receiving empiric intraoperative VPT and those receiving VC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.